Meeting
2020 ASCO Virtual Scientific Program
A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors.
Presenter
Filip Janku, MD, PhD
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT04096638
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS3162)
DOI
10.1200/JCO.2020.38.15_suppl.TPS3162
Abstract #
TPS3162
Poster Bd #
226
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors.
Speaker: Jacob Stephen Thomas, MD
Speaker: Panel Discussion
Videos & Slides
2023 ASCO Annual Meeting
First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors.
Speaker: David Sommerhalder, MD
Videos & Slides
2023 ASCO Genitourinary Cancers Symposium
Panelist
Speaker: Pauline Filippou, MD